Results 151 to 160 of about 202,135 (263)

Commentary: Additional observations on the skeleton of a juvenile Gryposaurus notabilis (Ornithischia: Hadrosauridae)

open access: yes
The Anatomical Record, EarlyView.
Jordan C. Mallon   +3 more
wiley   +1 more source

Gluteal Undersurface Concealed Crescent Injury Endoscopic Deep Surface Repair

open access: yesArthroscopy Techniques, EarlyView.
Abstract Partial‐thickness articular‐sided gluteus medius and minimus tears—referred to as gluteal undersurface concealed crescent injury lesions—can cause debilitating pain. Persistent symptoms despite nonoperative care indicate operative management. Conventional endoscopic repair techniques for partial‐thickness gluteal tears have commonly involved a
Bryant P. Elrick   +5 more
wiley   +1 more source

Don't give up on politics. [PDF]

open access: yesEur J Public Health
Burris S.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy